Overview

A Study to Evaluate the Tolerability and Efficacy of Tamsulosin 0.4mg OCAS Formulation in Patients Who Are Unsatisfied With the Treatment of Tamsulosin 0.2mg Conventional Formulation

Status:
Completed

Trial end date:
2015-01-01

Target enrollment:

Participant gender:

Summary

This is an open-label, single-arm, prospective interventional study to assess the tolerability and efficacy of Harnalidge® OCAS® 0.4 mg in Taiwan patients who are unsatisfied with tamsulosin 0.2 mg for the treatment of lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH).

Phase:

Phase 4

Details

Lead Sponsor:

Astellas Pharma Inc

Collaborator:

Astellas Pharma Taiwan, Inc.

Treatments:

Tamsulosin